Oncology
(1) Cyclin-K Degrader for Solid Tumors
iLeadBMS is developing a potentially first-in-class, orally available small molecule Cyclin-K degrader for various solid tumors including gastric, breast and colorectal cancers. Our compound acts as a Cyclin-K molecular glue, a highly promising type of Targeted Protein Degrader (TPD) and, has demonstrated a potent growth inhibition in various animal models including the HER2 negative gastric cancer and TNBC models. Based on the currently available data, it is anticipated that our Cyclin-K degrader has a potential to be developed as an intermittent oral monotherapy for many difficult solid tumors including those without identifiable drivers.
(2) SOS1 Inhibitor for RAS Driven Cancers
iLeadBMS is developing a potentially best-in-class, orally available small molecule SOS1 inhibitor for any RAS driven cancers. Our SOS1 inhibitor has a broad activity profile against various KRAS/RAS alleles including KRAS G12C, G12D, G12V and G13C. While our compound has demonstrated clear efficacy in animal models as a monotherapy, there was significant synergistic efficacy when combined with a KRAS inhibitor. Based on these promising preliminary results, it is anticipated that our SOS1 inhibitor can be developed as a powerful combination agent of choice for a broad type of KRAS inhibitors including both selective and the pan types.